carcinoma-associated antigen 17-1A

10/01/1999 - "Therefore, a better understanding of the biology of the 17-1A antigen may result in improved strategies for the treatment and diagnosis of human carcinomas. "
08/15/2000 - "The purpose of our study was to test whether the 17-1A antigen is expressed on primary and metastatic NSCLC carcinoma cells. "
10/01/1987 - "The authors report a study designed to evaluate the degree of heterogeneity of 17-1A antigen expression among primary and metastatic human colon carcinomas. "
07/15/1986 - "The 17-1A antigen (17-1A Ag) is broadly distributed in normal epithelial tissues and is also found in various types of carcinoma. "
11/15/1988 - "Enhanced cytotoxicity against colon carcinoma by combinations of noncompeting monoclonal antibodies to the 17-1A antigen."

05/01/2002 - "A tumor cell enrichment technique, applied in 70 patients prior to immunocytochemistry using dynabeads directly coupled to an antibody (BerEp4) targeting the 17-1A antigen, did not enhance the detection rate of disseminated tumor cells in this patient group. "
10/01/1999 - "In this review the properties of the 17-1A antigen are discussed concerning tumor biology and the function of the molecule. "
11/15/1988 - "Under suboptimum conditions, the combination of noncompeting mAbs to the 17-1A antigen resulted in tumor cell cytotoxicity which was synergistic to the lysis obtained with the respective mAbs alone. "
10/01/1987 - "This case showed variation in tumor differentiation and corresponding variation in 17-1A antigen expression. "
02/01/1999 - "The purpose of this study was to compare the expression of 17-1A antigen in colorectal tumors versus breast cancers. "

02/01/1999 - "The 17-1A antigen is already used as a target for specific immunotherapy in colorectal cancer. "
02/01/1999 - "The purpose of this study was to compare the expression of 17-1A antigen in colorectal tumors versus breast cancers. "
05/01/2001 - "Antibody selection was carried out against the epithelial cell adhesion molecule (EpCAM) or 17-1A antigen, that in a clinical trial had been successfully used as a target for antibody therapy of minimal residual colorectal cancer. "
11/01/2001 - "Expression of 17-1A antigen and complement resistance factors CD55 and CD59 on liver metastasis in colorectal cancer."
07/18/1995 - "One specificity of the two Fv fragments is directed against the CD3 antigen of human T cells and the other is directed against the epithelial 17-1A antigen; the latter had been found in a clinical trial to be a suitable target for antibody therapy of minimal residual colorectal cancer. "

11/01/1994 - "Studies on 17-1A antigen gene regulation in nonexpressing A549 and A431 cells, as compared to expressing pancreatic carcinoma (Capan 2) cells, reveal a complex mechanism of repression of this gene."
11/01/1994 - "Elements controlling high expression of the 17-1A antigen gene in pancreatic carcinoma cells (Capan 2) reside within the two regions: proximal (-193 to +3) and distal (-877 to -518). "
01/01/1998 - "The baculovirus-derived extracellular domain of the CO17-1A antigen induced cellular and/or humoral immune responses in curatively resected colorectal and pancreatic cancer patients after at least three applications of the vaccine. "
09/01/1989 - "In pancreatic cancer, 17-1A antigen was present in 87% of cases and TAG-72 antigen was present in 92% of cases. "

09/01/1999 - "Expression of the 17-1A antigen in gastric and gastro-oesophageal junction adenocarcinomas: a potential immunotherapeutic target?"
01/01/1991 - "These results suggest that 99mTc 323/A3 Fab' can detect 17-1A antigen and may have potential clinical utility for the rapid diagnostic imaging of adenocarcinomas."
10/01/1987 - "Of 36 additional malignant tumors that were not of colonic epithelial origin, adenocarcinomas of the stomach, duodenum, endometrium, ovary, and breast showed 17-1A antigen expression."
10/01/1987 - "In 16 cases that had both primary and metastatic adenocarcinomas or multiple metastatic tumors, 17-1A antigen expression was similar among the tumor sites except for one case. "
09/01/1999 - "The high incidence of expression of the 17-1A antigen in patients with gastric and gastro-oesophageal junction adenocarcinomas suggests a potential role for these antibodies as an adjuvant treatment for these common cancers."